迪哲医药:启动H股上市筹备,加速国际化布局

Core Viewpoint - The company, Dize Pharmaceutical, announced its plan to issue overseas listed foreign shares (H shares) and list on the main board of the Hong Kong Stock Exchange to enhance its global strategy and brand image [1] Group 1: Strategic Intent - The issuance of H shares aims to deepen the company's globalization strategy and improve its international brand image [1] - The company intends to further enhance its core competitiveness through this issuance [1] Group 2: Shareholder Considerations - The company will take into account the interests of existing shareholders and the conditions of domestic and international capital markets when deciding on the timing and window for the issuance [1] - The decision to proceed with the issuance will be valid for 24 months from the approval of the shareholders' meeting, with the possibility of extension [1]